Hidehiro Kohzuki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hidehiro Kohzuki has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Eiichi Ishikawa
Department of Neurosurgery, Institute of Medicine, University of Tsukuba, Ibaraki, Japan
3 shared publications - Masahide Matsuda
Department of Neurosurgery, Institute of Medicine, University of Tsukuba
3 shared publications Eiichi Ishikawa
Department of Neurosurgery, Faculty of Medicine, University of Tsukuba
2 shared publicationsTakao Tsurubuchi
Department of Neurosurgery, Ibaraki Prefectural Central Hospital
2 shared publicationsMasahide Matsuda
Department of Neurosurgery, Faculty of Medicine, University of Tsukuba
1 shared publicationNarushi Sugii
Department of Neurosurgery, Faculty of Medicine, University of Tsukuba
1 shared publication
Latest Publications
- Open Access
Postoperative Diffusion-Weighted Imaging Hyperintensity Following Combined Photodynamic Diagnosis and Therapy Using 5-Aminolevulinic Acid and Talaporfin Sodium in Malignant Brain Tumors
Background/Objective: Intraoperative local photodynamic therapy (PDT) using talaporfin sodium (TS) and photodynamic diagnosis (PDD) with 5-aminolevulinic acid (5-ALA) are valuable adjuncts in the treatment of malignant brain tumors. Although their concomitant use was previously contraindicated due to photosensitivity concerns, a 2022 regulatory revision permitted their combined application. Transient postoperative hyperintensity on diffusion-weighted imaging (DWI) at the irradiation site serves as a biomarker for PDT effects, but the radiological and clinical impact of combining 5-ALA and TS remains unclarified. To compare and evaluate postoperative DWI findings and clinical outcomes in patients undergoing TS-PDT with or without concomitant 5-ALA-guided PDD. Methods: This retrospective study analyzed 34 patients with recurrent primary malignant brain tumors who underwent TS-PDT between January 2019 and November 2025. Patients were divided into a TS alone group (n = 19) and a TS + 5-ALA group (n = 15). Postoperative DWI hyperintensity thickness and minimum apparent diffusion coefficient (ADC) values at the laser irradiation site were measured. Adverse events including photosensitivity were also compared. Results: No significant differences were observed between the TS alone and TS + 5-ALA groups in DWI hyperintensity thickness (3.71 mm vs. 3.90 mm; p = 0.703 or median ADC values (601.0 × 10−6 mm2/s vs. 527.0 × 10−6 mm2/s; p = 0.205). Furthermore, there were no significant differences in the incidence of photosensitivity and liver enzyme elevation. Conclusions: Concomitant use of 5-ALA-PDD and TS-PDT can be used without worsening DWI findings at the PD laser irradiation site.
Open AccessPostoperative Diffusion-Weighted Imaging Hyperintensity Following Combined Photodynamic Diagnosis and Therapy Using 5-Aminolevulinic Acid and Talaporfin Sodium in Malignant Brain Tumors
Background/Objective: Intraoperative local photodynamic therapy (PDT) using talaporfin sodium (TS) and photodynamic diagnosis (PDD) with 5-aminolevulinic acid (5-ALA) are valuable adjuncts in the treatment of malignant brain tumors. Although their concomitant use was previously contraindicated due to photosensitivity concerns, a 2022 regulatory revision permitted their combined application. Transient postoperative hyperintensity on diffusion-weighted imaging (DWI) at the irradiation site serves as a biomarker for PDT effects, but the radiological and clinical impact of combining 5-ALA and TS remains unclarified. To compare and evaluate postoperative DWI findings and clinical outcomes in patients undergoing TS-PDT with or without concomitant 5-ALA-guided PDD. Methods: This retrospective study analyzed 34 patients with recurrent primary malignant brain tumors who underwent TS-PDT between January 2019 and November 2025. Patients were divided into a TS alone group (n = 19) and a TS + 5-ALA group (n = 15). Postoperative DWI hyperintensity thickness and minimum apparent diffusion coefficient (ADC) values at the laser irradiation site were measured. Adverse events including photosensitivity were also compared. Results: No significant differences were observed between the TS alone and TS + 5-ALA groups in DWI hyperintensity thickness (3.71 mm vs. 3.90 mm; p = 0.703 or median ADC values (601.0 × 10−6 mm2/s vs. 527.0 × 10−6 mm2/s; p = 0.205). Furthermore, there were no significant differences in the incidence of photosensitivity and liver enzyme elevation. Conclusions: Concomitant use of 5-ALA-PDD and TS-PDT can be used without worsening DWI findings at the PD laser irradiation site.
- Open Access
- 15 April 2026
- Published by Japan Society for Laser Surgery and Medicine in THE JOURNAL OF JAPAN SOCIETY FOR LASER SURGERY AND MEDICINE
- Vol. 47 (1) , 93-96
Intraoperative Photodynamic Diagnosis Using 5-Aminolevulinic Acid Combined with Talaporfin Sodium Photodynamic Therapy for Recurrent High Grade Glioma—Adverse Event and Counterpart—
2022年に5-アミノレブリン酸(5-amibolevlinic acid: 5-ALA)の添付文書が改定され,5-ALAとタラポルフィンナトリウム(talaporfin sodium: TS)の併用が可能となった.これによって5-ALAを使った光線力学診断(photodynamic diagnosis: PDD)による摘出率の改善に加えて,TSをつかった光線力学的療法(photodynamic therapy: PDT)による殺細胞効果によって予後改善が期待される.一方で5-ALAとTSには光線過敏症をはじめ,肝機能異常や低血圧などの注意すべき有害事象が存在する.本稿では5-ALAとTS併用の際に注意すべき有害事象とその対策について検討する.また我々は再発悪性神経膠腫に対して5-ALA-PDDとTS-PDTを併用した手術に行っているが,TSと同様の遮光管理で光線過敏症は増加せずその他の有害事象も重篤なものはなかった.5-ALA-PDDとTS-PDTの併用は安全に行える手法である.
- 15 April 2026
- Published by Japan Society for Laser Surgery and Medicine in THE JOURNAL OF JAPAN SOCIETY FOR LASER SURGERY AND MEDICINE
- Vol. 47 (1) , 93-96
Open AccessIntraoperative Photodynamic Diagnosis Using 5-Aminolevulinic Acid Combined with Talaporfin Sodium Photodynamic Therapy for Recurrent High Grade Glioma—Adverse Event and Counterpart—
2022年に5-アミノレブリン酸(5-amibolevlinic acid: 5-ALA)の添付文書が改定され,5-ALAとタラポルフィンナトリウム(talaporfin sodium: TS)の併用が可能となった.これによって5-ALAを使った光線力学診断(photodynamic diagnosis: PDD)による摘出率の改善に加えて,TSをつかった光線力学的療法(photodynamic therapy: PDT)による殺細胞効果によって予後改善が期待される.一方で5-ALAとTSには光線過敏症をはじめ,肝機能異常や低血圧などの注意すべき有害事象が存在する.本稿では5-ALAとTS併用の際に注意すべき有害事象とその対策について検討する.また我々は再発悪性神経膠腫に対して5-ALA-PDDとTS-PDTを併用した手術に行っているが,TSと同様の遮光管理で光線過敏症は増加せずその他の有害事象も重篤なものはなかった.5-ALA-PDDとTS-PDTの併用は安全に行える手法である.
- Open Access
- 15 July 2023
- Published by Japan Society for Laser Surgery and Medicine in THE JOURNAL OF JAPAN SOCIETY FOR LASER SURGERY AND MEDICINE
- Vol. 44 (2) , 124-128
Adverse Events and Countermeasures of 5-Aminolevulinic Acid and Taraporfin Sodium
悪性神経膠腫に対する5アミノレブリン酸(5-Amibolevlinic Acid: 5ALA)を用いた光線力学診断(Photodynamic diagnosis: PDD)とタラポルフィンナトリウム(talaporfin sodium: TS)を用いた光線力学療法(Photodynamic Therapy: PDT)は,摘出率の向上や生存期間中央値の改善に寄与し,本邦で広く用いられている.いずれも光感受性物質と特定波長のレーザー光を用いる手法で有害事象として光線過敏症がよく知られているが,その他の有害事象について脳外科領域での報告は少ない.我々は5ALA内服後に著明な低血圧を呈し,手術開始時間が遅延した1例を経験した.またTS-PDT後の遮光管理中にうつ状態となった1例を経験した.我々が経験した症例について報告し,5ALAとTSによる有害事象とその対策について考察する.
- 15 July 2023
- Published by Japan Society for Laser Surgery and Medicine in THE JOURNAL OF JAPAN SOCIETY FOR LASER SURGERY AND MEDICINE
- Vol. 44 (2) , 124-128
Open AccessAdverse Events and Countermeasures of 5-Aminolevulinic Acid and Taraporfin Sodium
悪性神経膠腫に対する5アミノレブリン酸(5-Amibolevlinic Acid: 5ALA)を用いた光線力学診断(Photodynamic diagnosis: PDD)とタラポルフィンナトリウム(talaporfin sodium: TS)を用いた光線力学療法(Photodynamic Therapy: PDT)は,摘出率の向上や生存期間中央値の改善に寄与し,本邦で広く用いられている.いずれも光感受性物質と特定波長のレーザー光を用いる手法で有害事象として光線過敏症がよく知られているが,その他の有害事象について脳外科領域での報告は少ない.我々は5ALA内服後に著明な低血圧を呈し,手術開始時間が遅延した1例を経験した.またTS-PDT後の遮光管理中にうつ状態となった1例を経験した.我々が経験した症例について報告し,5ALAとTSによる有害事象とその対策について考察する.
- Open Access
- 15 July 2023
- Published by Japan Society for Laser Surgery and Medicine in THE JOURNAL OF JAPAN SOCIETY FOR LASER SURGERY AND MEDICINE
- Vol. 44 (2) , 186-190
Usefulness of Photodynamic Diagnosis with Talaporfin Sodium in Surgery for Recurrent High Grade Glioma
悪性神経膠腫に対するタラポルフィンナトリウム(talaporfin sodium: TS)を用いた光線力学的診断(photodynamic diagnosis: PDD)における顕微鏡下の特異的腫瘍蛍光強度に関する報告は少なく,今回再発悪性神経膠腫に対するTS-PDDの腫瘍特異的蛍光強度と摘出率や病理学的所見との関係ついて後方視的に検討した.7症例中2例は蛍光強陽性,4例は弱陽性,1例は陰性で,弱陽性例では腫瘍周囲組織とのコントラストがつきにくかった.現状では強陽性例が少なく,TS-PDDを再発悪性神経膠腫に対する摘出率の向上を目的として5-アミノレブリン酸(5-Aminolevlinic acid: 5ALA)-PDD同様に用いることは難しい.蛍光強陽性例に絞った使用やコントラストを増強するための増感剤の開発などさらなる研究が望まれる.
- 15 July 2023
- Published by Japan Society for Laser Surgery and Medicine in THE JOURNAL OF JAPAN SOCIETY FOR LASER SURGERY AND MEDICINE
- Vol. 44 (2) , 186-190
Open AccessUsefulness of Photodynamic Diagnosis with Talaporfin Sodium in Surgery for Recurrent High Grade Glioma
悪性神経膠腫に対するタラポルフィンナトリウム(talaporfin sodium: TS)を用いた光線力学的診断(photodynamic diagnosis: PDD)における顕微鏡下の特異的腫瘍蛍光強度に関する報告は少なく,今回再発悪性神経膠腫に対するTS-PDDの腫瘍特異的蛍光強度と摘出率や病理学的所見との関係ついて後方視的に検討した.7症例中2例は蛍光強陽性,4例は弱陽性,1例は陰性で,弱陽性例では腫瘍周囲組織とのコントラストがつきにくかった.現状では強陽性例が少なく,TS-PDDを再発悪性神経膠腫に対する摘出率の向上を目的として5-アミノレブリン酸(5-Aminolevlinic acid: 5ALA)-PDD同様に用いることは難しい.蛍光強陽性例に絞った使用やコントラストを増強するための増感剤の開発などさらなる研究が望まれる.
- Open Access
- 16 December 2022
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 13, 583
Timing of bevacizumab administration after biopsy for unresectable newly diagnosed glioblastoma
Background: Recent studies have revealed that bevacizumab (BEV) can improve the survival of patients with newly diagnosed unresectable glioblastoma (GBM) with poor performance status. For patients who develop early clinical deterioration, early initiation of BEV would be beneficial. However, the safety and feasibility of early initiation of BEV remain to be determined because of the lack of studies addressing adverse events associated with BEV initiation <28 days after surgery. The aim of this study was to analyze the risks and benefits of early BEV administration after biopsy in patients with newly diagnosed GBM. Methods: Thirty-one consecutive patients with newly diagnosed GBM who underwent biopsy followed by BEV administration were investigated. The relationships between the timing of BEV administration and treatment response, survival outcome, and adverse events were analyzed. Results: Response rates based on the RANO criteria and overall survival times were similar between the early and standard BEV groups. No wound dehiscence was observed in the early BEV group, and only one case was observed in the standard BEV group. Patients in the early BEV group were more likely to have undergone biopsy with a smaller skin incision than those in the standard BEV group. Equivalent treatment effects of BEV were achieved in patients who developed early clinical deterioration and those without clinical deterioration. Conclusion: Early BEV administration is effective in controlling early clinical deterioration and does not increase the risk of wound-healing complications. Further studies with larger numbers of patients are needed to validate our results.
- 16 December 2022
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 13, 583
Open AccessTiming of bevacizumab administration after biopsy for unresectable newly diagnosed glioblastoma
Background: Recent studies have revealed that bevacizumab (BEV) can improve the survival of patients with newly diagnosed unresectable glioblastoma (GBM) with poor performance status. For patients who develop early clinical deterioration, early initiation of BEV would be beneficial. However, the safety and feasibility of early initiation of BEV remain to be determined because of the lack of studies addressing adverse events associated with BEV initiation <28 days after surgery. The aim of this study was to analyze the risks and benefits of early BEV administration after biopsy in patients with newly diagnosed GBM. Methods: Thirty-one consecutive patients with newly diagnosed GBM who underwent biopsy followed by BEV administration were investigated. The relationships between the timing of BEV administration and treatment response, survival outcome, and adverse events were analyzed. Results: Response rates based on the RANO criteria and overall survival times were similar between the early and standard BEV groups. No wound dehiscence was observed in the early BEV group, and only one case was observed in the standard BEV group. Patients in the early BEV group were more likely to have undergone biopsy with a smaller skin incision than those in the standard BEV group. Equivalent treatment effects of BEV were achieved in patients who developed early clinical deterioration and those without clinical deterioration. Conclusion: Early BEV administration is effective in controlling early clinical deterioration and does not increase the risk of wound-healing complications. Further studies with larger numbers of patients are needed to validate our results.